Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 160 publications.
Skip to main content
Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster presented at the ISPOR 2025; May 13, 2025. Montréal, Canada.
George S, Carrico J, Hicks KA, Loukov D, Ng C, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada. BMC Health Serv Res. 2025 Apr 25;25(1):604. doi: 10.1186/s12913-025-12550-x
Shah HA, Jutlla G, Herrera-Restrepo O, Graham J, Hicks KA, Carrico J, Grace M, Clements DE, Burman C, Sohn WY, Kuylen E, Begum S, Kocaata Z. Public health impact of introducing a pentavalent vaccine against invasive meningococcal disease in the United States. Pharmacoeconomics. 2025 Mar;43(3):311-29. doi: 10.1007/s40273-024-01439-y
Viguerie A, O'Shea J, Johnston M, Schreiber D, Adams J, Bates L, Carrico J, Hicks KA, Lyles CM, Farnham PG. Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines. AIDS. 2025 Feb 5. doi: 10.1097/QAD.0000000000004144
Hicks KA, Ghaswalla P, Carrico J, Anderson S, Novy P, Hogea C, Hayney MS. Estimating the cost of university-based outbreaks of serogroup B meningococcal disease with different pre-matriculation vaccination policies in the United States. J Am Coll Health. 2024 Nov 21;72(9):3439-48. doi: 10.1080/07448481.2022.2163854
Carrico J, Hicks KA, Wilson E, Panozzo CA, Ghaswalla P. The annual economic burden of respiratory syncytial virus in adults in the United States. J Infect Dis. 2024 Aug 16;230(2):e342-52. doi: 10.1093/infdis/jiad559
Shah HA, Herrera-Restrepo O, Jutlla G, Carrico J, Hicks K, Kuylen E, Begum S, Clements D, Burman C, Sohn WY, Kocaata Z. Public health impact of MENABCWY vaccination in adolescents and MENB vaccination in infants in the United States. Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w
Viguerie A, Jacobson EU, Hicks KA, Bates L, Carrico J, Honeycutt A, Lyles C, Farnham PG. Assessing the impact of COVID-19 on HIV outcomes in the United States: a modeling study. Sex Transm Dis. 2024 Apr 1;51(4):299-304. doi: 10.1097/OLQ.0000000000001935
Jacobson E, Viguerie A, Hicks K, Bates L, Honeycutt A, Carrico J, Farnham P. Strategies for eliminating racial/ethnic disparities in HIV incidence in the United States. Poster presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI); March 5, 2024. Denver, CO.
Ghaswalla P, Carrico J, Hicks KA. The annual economic burden of respiratory syncytial virus in adults in the United States. Presented at the 2024 Biomedical Advanced Research and Development Authority George Risi Memorial Journal Club; January 22, 2024.
Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc Stephane, Hicks KA, Poston S, Carpenter CF. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023 Dec 31;19(1):2167907. doi: 10.1080/21645515.2023.2167907
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Viguerie A, Jacobson EU, Hicks K, Bates L, Carrico J, Honeycutt A, Lyles C, Farnham PG. Assessing the impact of COVID-19 on HIV outcomes: a modeling study. Poster presented at the 2023 INFORMS Annual Meeting; October 16, 2023. Phoenix, AR.
Ghaswalla P, Hitchens A, Candrilli SD, Carrico J, Hicks KA, Wilson E, Mehta D, Panozzo CA. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018. Poster presented at the IDWeek 2023; October 12, 2023. Boston, MA.
George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. Poster presented at the 2023 Canadian Immunization Conference; April 25, 2023. Ottawa, Canada. Previously presented at the 2022 Canadian Association for Population Therapeutics Conference.
Carrico J, Hicks K, Panozzo CA, Ghaswalla P. Economic burden of respiratory syncytial virus in adults in the United States. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec; 25(12):S65. doi: 10.1016/j.jval.2022.09.315
Salem A, Curran D, Carrico J, La EM, Lorenc S, Hicks K, Poston S, Carpenter CF. Public health impact and cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S159. doi: 10.1016/j.jval.2022.09.767
Poirrier JE, DeMartino JK, Nagar S, Carrico J, Hicks K, Meyers J, Stoddard J. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022 Nov;18(5):2040328. doi: 10.1080/21645515.2022.2040328
George S, Carrico J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Updated cost-utility and public health impact of recombinant zoster vaccine (RZV) in Canadians aged 50 years and older. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.
George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.
Jacobson EU, Hicks KA, Carrico J, Purcell DW, Green TA, Mermin JH, Farnham PG. Optimizing HIV prevention efforts to achieve EHE incidence targets. J Acquir Immune Defic Syndr. 2022 Apr;89(4):373-80. doi: 10.1097/QAI.0000000000002885
Chen YH, Farnham PG, Hicks KA, Sansom SL. Estimating the HIV effective reproduction number in the United States and evaluating HIV elimination strategies. J Public Health Manag Pract. 2022 Mar;28(2). doi: 10.1097/PHH.0000000000001397
Curran D, Patterson B, Carrico J, Salem A, La E, Lorenc S, Hicks K, Poston S, Carpenter C. Cost-effectiveness analysis of recombinant Zoster vaccine for the prevention of herpes Zoster in immunocompromised adults diagnosed with select cancers in the United States. Poster presented at the 2021 Lymphoma and Myeloma (L&M) Virtual Congress; October 2021. [abstract] Am J Hematol. 2021 Oct 15; 96(S1):S26. doi: 10.1002/ajh.26351
Curran D, Patterson BJ, Carrico J, Salem AE, La EM, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the IDWeek 2021 Virtual Conference; September 29, 2021.
La E, Poston S, Curran D, Lorenc S, Salem AE, Carrico J, Hicks KA, Anderson S, Carpenter CF. Cost-effectiveness analysis of recombinant zoster vaccine for vaccinating immunocompromised adults against Herpes Zoster in the United States. Presented at the ACIP Herpes Zoster Working Group; April 2021. Atlanta, GA.
Hicks KA, Ghaswalla P, Carrico J, Anderson S, Novy P, Hogea C, Hayney MS. Estimations of the cost of university-based outbreaks of serogroup B meningococcal disease in the United States. Poster presented at the Pediatric Academic Societies (PAS) 2021 Virtual Meeting; April 2021.
Jacobson E, Hicks KA, Carrico J, Purcell D, Green T, Mermin J, Farnham P. Optimizing HIV prevention efforts to achieve EHE incidence targets. Presented at the 2021 Virtual Conference on Retroviruses and Opportunistic Infections (CROI); March 6, 2021.
Sansom SL, Hicks KA, Carrico J, Jacobson EU, Shrestha RK, Green TA, Purcell DW. Optimal allocation of societal HIV prevention resources to reduce HIV incidence in the United States. Am J Public Health. 2021 Jan;111(1):150-8. doi: 10.2105/AJPH.2020.305965
Poirrier J-E, Carrico J, DeMartino JK, Hicks KA, Stoddard JJ, Nagar S, Meyers J. The potential for reducing opioid and analgesic prescriptions via herpes zoster vaccination. Poster presented at the IDWeek 2020 Virtual Conference; October 21, 2020.
Jacobson E, Hicks K, Carrico J, Sansom SL. Optimizing HIV prevention efforts without new investment can reduce incidence. Presented at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI); March 2020. Boston, MA.
Standaert B, Van Vlaenderen I, Van Bellinghen LA, Talbird SE, Hicks K, Carrico J, Buck PO. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019 Nov 22. doi: 10.1007/s40258-019-00534-y
Khurana N, Farnham PG, Hicks KA, Carrico J, Sansom S. Impact of targeting pre-exposure prophylaxis to individual transmission groups in the United States. Poster presented at the 2019 INFORMS Annual Meeting; October 20, 2019. Seattle, WA.
Hicks K, Earnshaw S. Demonstrating the use of constrained optimization on a real-world problem. Presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.
Khurana N, Farnham P, Hicks K, Carrico J, Sansom S. Cost-effectiveness of delivering pre-exposure prophylaxis for different HIV care-continuum levels in the United States. Poster presented at the 2019 National HIV Prevention Conference; March 20, 2019. Atlanta, GA.
Farnham P, Jacobson E, Chen Y-H, Hicks K, Sansom S. The impact of maintaining viral suppression on reducing HIV incidence: congruence of modeling results. Presented at the 2019 National HIV Prevention Conference; March 20, 2019. Atlanta, GA.
Curran D, Patterson BJ, Van-Oorschot D, Buck PO, Carrico J, Hicks KA, Lee B, Yawn BP. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765-71. doi: 10.1080/21645515.2018.1558689.
Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018 Aug 9;36(33):5037-45. doi: 10.1016/j.vaccine.2018.07.005